Search results for "Real"

showing 10 items of 4449 documents

Uncommon oral manifestation of lichen sclerosus: critical analysis of cases reported from 1957 to 2016

2017

Background Lichen sclerosus is a mucocutaneous autoimmune disease which might be initiated by infectious pathogens as Borrelia Bugrdorferi and HPV. This disease shows destructive potential and is rarely diagnosed in oral mucosa. The purpose of this paper is to evaluate the characteristics of cases described in literature from 1957 to 2016, looking to provide valuable evidence about clinicopathologic features of this disease. Material and Methods A MedLine search was performed aiming to find oral lichen sclerosus cases in literature and discuss its demographical and pathological characteristics as well as treatment methods performed for these cases. Results 34 oral lichen sclerosus cases wit…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentMucocutaneous zoneReviewDiseaseLichen sclerosusAsymptomaticYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineHumansOral mucosaYoung adultChildGeneral DentistryPathologicalAgedAutoimmune diseaseOral Medicine and Pathologyintegumentary systembusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologystomatognathic diseasesLichen Sclerosus et Atrophicusmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASFemaleSurgerymedicine.symptomMouth DiseasesbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

2016

AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician' s global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database. RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the averag…

AdultMalemedicine.medical_specialtyTime FactorsAnti-Inflammatory AgentsObservational StudySeverity of Illness IndexGolimumab03 medical and health sciences0302 clinical medicineGastrointestinal AgentsAdrenal Cortex HormonesInternal medicineHumansMedicineProspective StudiesTumor Necrosis Factor-alphabusiness.industryRemission InductionGastroenterologyAntibodies MonoclonalColonoscopyGeneral MedicineMiddle Agedmedicine.diseaseReal-life resultsUlcerative colitisdigestive system diseasesGolimumabTreatment OutcomeMulticenter studyUlcerative colitisSpain030220 oncology & carcinogenesisColitis UlcerativeDrug Therapy CombinationFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria

2019

Objectives: Treatment of chronic spontaneous urticaria (CSU) is based on evidence-based guidelines. However, specific patient needs and benefits from therapy have not been differentiated on the guideline level. The current study was designed to use the first part of the PBI, the PNQ, to characterize[for full text, please go to the a.m. URL]

AdultMalemedicine.medical_specialtyTime FactorsCross-sectional studyHealth StatusDermatologyDiseasePatient Care Planning030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineCost of IllnessQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansChronic UrticariaDisease burdenChronic urticariaAgedbusiness.industryPruritusPatient PreferenceGuidelineMiddle Aged610 Medical sciences; MedicineCross-Sectional StudiesPatient burden030228 respiratory systemddc: 610Quality of LifeItchingFemalemedicine.symptombusinessDecision Making SharedNeeds Assessment
researchProduct

The MOAHLFA index of irritant sodium lauryl sulfate reactions: first results of a multicentre study on routine sodium lauryl sulfate patch testing

2004

In a multicentre study of the German Contact Dermatitis Research Group, sodium lauryl sulfate (SLS) 0.25% and 0.5% aq. has been added to routine allergen patch tests to assess its properties as a convenient diagnostic indicator of individual susceptibility to irritation at the time of patch testing. Previous studies indicated that irritant SLS reactivity may be related to individual factors such as age and sex. As these factors are, in turn, among the important predictors of contact allergy to many allergens, e.g. summarized in the 'MOAHLFA index', the impact of the MOAHLFA factors on irritant SLS patch test reactivity, and thus a potential for confounding, was assessed in the 5971 particip…

AdultMalemedicine.medical_specialtyTime FactorsHand DermatosesDermatologyLeg Dermatosesmedicine.disease_causeLogistic regressionSeverity of Illness IndexDermatitis Atopic030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineAllergenRisk FactorsmedicineHumansImmunology and AllergyRisk factorintegumentary systemChemistryConfoundingAge FactorsSodium Dodecyl SulfatePatch testConfounding Factors EpidemiologicPatch Testsmedicine.diseaseDermatology3. Good healthSurgeryDermatitis Occupational030220 oncology & carcinogenesisToxicityIrritantsDermatitis IrritantFemaleDisease SusceptibilityIrritationContact dermatitisFacial DermatosesContact Dermatitis
researchProduct

Lower lip squamous cell carcinoma in patients with photosensitive disorders : analysis of cases treated at the Brazilian National Cancer Institute (I…

2017

Background Lower lip squamous cell carcinoma (LLSCC) is a common malignancy of the head and neck, being mainly a consequence of a chronic exposure to ultraviolet (UV) light solar radiation. Here, we evaluated the clinicopathological profile of patients with photosensitive disorders (xeroderma pigmentosum, lupus erythematosus and albinism) that developed LLSCC. Material and Methods Data from patients who had a diagnosed LLSCC with a prior xeroderma pigmentosum, lupus erythematosus or albinism diagnosis that were treated at INCA from 1999 to 2012 were collected from patients’ medical records (n=16). The control group was composed of 68 patients with LLSCC without a medical history of photosen…

AdultMalemedicine.medical_specialtyTime FactorsXeroderma pigmentosumAdolescentMalignancyYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineCarcinomaHumansPhotosensitivity Disordersskin and connective tissue diseasesChildGeneral DentistrySurvival analysisAgedRetrospective StudiesOral Medicine and PathologyLupus erythematosusSquamous Cell Carcinoma of Head and Neckbusiness.industryResearchAcademies and InstitutesMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyPrimary tumorExact testOtorhinolaryngologyHead and Neck Neoplasms030220 oncology & carcinogenesisLip NeoplasmsUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellPopulation studyFemaleSurgerybusinessBrazil
researchProduct

The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference

2016

Background The Angioedema Quality of Life Questionnaire (AE-QoL) has recently been developed and validated as the first specific patient-reported outcome tool to assess quality of life (QoL) impairment in recurrent angioedema patients. As of yet, its sensitivity to change and minimal clinically important difference (MCID) have not been established. Methods Recurrent angioedema patients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked to complete the AE-QoL along with the SF-12 and other anchors for QoL impairment and disease activity during routine care visits. The sensitivity to change of AE-QoL was determined by correlating changes in its scores over time …

AdultMalemedicine.medical_specialtyUrticariaClinical immunologyImmunologyMinimal Clinically Important DifferenceDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceSurveys and QuestionnairesHumansImmunology and AllergyMedicineAngioedemaSensitivity to changeskin and connective tissue diseasesRoutine careAngioedemabusiness.industryMinimal clinically important differenceReproducibility of ResultsMiddle Agedmedicine.diseasehumanities030228 respiratory systemChronic DiseaseHereditary angioedemaQuality of LifePhysical therapyFemalesense organsmedicine.symptombusinessAllergy
researchProduct

The Role of Interleukin 10 and 18 in Chronic Spontaneous Urticaria Pathogenesis in the Context of Angioedema Coexistence

2021

Chronic spontaneous urticaria (CSU) is defined using clinical symptoms as spontaneous occurrence of itchy wheals and/or angioedema for at least 6 weeks. Angioedema is underdiagnosed in CSU patients, and its presence has significant negative impact on health-related quality of life, daily activities, health care resource utilization, and work. Various cytokines have been found to be involved in pathogenesis of CSU. To study levels of interleukin (IL)-10 and IL-18 in CSU patients and to look for the differences in CSU subgroups divided with regard to angioedema reoccurrence, we included consecutive CSU patients into the study. To assess disease activity, urticaria activity score was used. In …

AdultMalemedicine.medical_specialtyUrticariaImmunologyContext (language use)DiseasePathogenesisYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeVirologyInternal medicinemedicineHumansIn patientAngioedemaAgedAngioedemabusiness.industryInterleukin-18InterleukinCell BiologyMiddle AgedInterleukin-10Interleukin 10030228 respiratory systemChronic DiseaseFemaleDisease Susceptibilitymedicine.symptombusinessBiomarkersJournal of Interferon and Cytokine Research
researchProduct

Comparison and interpretability of the available urticaria activity scores

2017

The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r = .90, P < .001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate, and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40. UAS7 values were slightly, but significantly lower as compare…

AdultMalemedicine.medical_specialtyUrticariaImmunologySeverity of Illness IndexMean differenceDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineOutcome Assessment Health CaremedicineHumansImmunology and AllergyIn patientRoutine careInterpretabilitybusiness.industryReproducibility of ResultsGold standard (test)Middle AgedSurgeryClinical trial030228 respiratory systemFemalebusinessBiomarkersAllergy
researchProduct

Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.

2016

AdultMalemedicine.medical_specialtyUrticariaImmunologyTreatment outcomePlacebo-controlled studyMEDLINEDrug ResistanceHistamine AntagonistsOmalizumabOmalizumablaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansbusiness.industryMiddle AgedSymptomatic dermographismTreatment Outcome030228 respiratory systemMulticenter studyFemalebusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial

2016

AdultMalemedicine.medical_specialtyUrticariaImmunologyTreatment outcomePlacebo-controlled studyMEDLINEOmalizumabOmalizumabCold urticarialaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and Allergybusiness.industryMiddle Agedmedicine.diseaseCold TemperatureTreatment Outcome030228 respiratory systemMulticenter studyPhysical therapyFemalebusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct